Literature DB >> 29660422

Hair disorders in patients with cancer.

Azael Freites-Martinez1, Jerry Shapiro2, Shari Goldfarb3, Julie Nangia4, Joaquin J Jimenez5, Ralf Paus6, Mario E Lacouture7.   

Abstract

Cytotoxic chemotherapies, molecularly targeted therapies, immunotherapies, radiotherapy, stem cell transplants, and endocrine therapies may lead to hair disorders, including alopecia, hirsutism, hypertrichosis, and pigmentary and textural hair changes. The mechanisms underlying these changes are varied and remain incompletely understood, hampering the development of preventive or therapeutic guidelines. The psychosocial impact of chemotherapy-induced alopecia has been well documented primarily in the oncology literature; however, the effect of other alterations, such as radiation-induced alopecia, hirsutism, and changes in hair color or texture on quality of life have not been described. This article reviews clinically significant therapy-related hair disorders in oncology patients, including the underlying pathophysiological mechanisms, severity grading scales, patient-reported quality of life questionnaires, management strategies, and future translational research opportunities.
Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anagen effluvium; brittleness; cancer patients; catagen effluvium; chemotherapy-induced alopecia; curling; depigmentation; eyebrow alopecia; eyelash alopecia; hair repigmentation; hirsutism; hyperpigmentation; hypertrichosis; hypopigmentation; straightening; trichomegaly

Mesh:

Substances:

Year:  2018        PMID: 29660422      PMCID: PMC6186204          DOI: 10.1016/j.jaad.2018.03.055

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  162 in total

1.  Scalp cooling therapy and cytotoxic treatment.

Authors:  S A Forsberg
Journal:  Lancet       Date:  2001-04-07       Impact factor: 79.321

2.  CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.

Authors:  T André; C Louvet; F Maindrault-Goebel; C Couteau; M Mabro; J P Lotz; V Gilles-Amar; M Krulik; E Carola; V Izrael; A de Gramont
Journal:  Eur J Cancer       Date:  1999-09       Impact factor: 9.162

3.  Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study.

Authors:  J P Curtin; J A Blessing; K D Webster; P G Rose; A R Mayer; W C Fowler; J H Malfetano; R D Alvarez
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

Authors:  J Sjöström; C Blomqvist; H Mouridsen; A Pluzanska; S Ottosson-Lönn; N O Bengtsson; B Ostenstad; I Mjaaland; M Palm-Sjövall; E Wist; V Valvere; H Anderson; J Bergh
Journal:  Eur J Cancer       Date:  1999-08       Impact factor: 9.162

5.  Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma.

Authors:  P S Gill; A Tulpule; B M Espina; S Cabriales; J Bresnahan; M Ilaw; S Louie; N F Gustafson; M A Brown; C Orcutt; B Winograd; D T Scadden
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

6.  Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

Authors:  M Ranson; N Davidson; M Nicolson; S Falk; J Carmichael; P Lopez; H Anderson; N Gustafson; A Jeynes; G Gallant; T Washington; N Thatcher
Journal:  J Natl Cancer Inst       Date:  2000-07-05       Impact factor: 13.506

7.  p53 is essential for chemotherapy-induced hair loss.

Authors:  V A Botchkarev; E A Komarova; F Siebenhaar; N V Botchkareva; P G Komarov; M Maurer; B A Gilchrest; A V Gudkov
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

8.  Absorbed dose and deterministic effects to patients from interventional neuroradiology.

Authors:  R B Mooney; C S McKinstry; H A Kamel
Journal:  Br J Radiol       Date:  2000-07       Impact factor: 3.039

Review 9.  Psychological sequelae and alopecia among women with cancer.

Authors:  E L McGarvey; L D Baum; R C Pinkerton; L M Rogers
Journal:  Cancer Pract       Date:  2001 Nov-Dec

10.  Prevention of chemotherapy-induced alopecia using an effective scalp cooling system.

Authors:  P Katsimbri; A Bamias; N Pavlidis
Journal:  Eur J Cancer       Date:  2000-04       Impact factor: 9.162

View more
  14 in total

Review 1.  Pharmacological Ascorbate as a Means of Sensitizing Cancer Cells to Radio-Chemotherapy While Protecting Normal Tissue.

Authors:  Joshua D Schoenfeld; Matthew S Alexander; Timothy J Waldron; Zita A Sibenaller; Douglas R Spitz; Garry R Buettner; Bryan G Allen; Joseph J Cullen
Journal:  Semin Radiat Oncol       Date:  2019-01       Impact factor: 5.934

2.  Clinical and sociodemographic determinants of disease-specific health-related quality of life in long-term breast cancer survivors.

Authors:  Daniela Doege; Melissa S Y Thong; Lena Koch-Gallenkamp; Heike Bertram; Andrea Eberle; Bernd Holleczek; Alice Nennecke; Ron Pritzkuleit; Annika Waldmann; Sylke R Zeissig; Hermann Brenner; Volker Arndt
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-25       Impact factor: 4.322

3.  Flame Hair: Auxiliary Trichoscopic Finding in Radiotherapy-Induced Alopecia.

Authors:  Ana Beatriz Silva Lima; Fernanda Tirelli Rocha; Fernanda André Martins Cruz Perecin; João Carlos Lopes Simão; Andrezza Telles Westin; Marco Andrey Cipriani Frade
Journal:  Skin Appendage Disord       Date:  2021-02-18

Review 4.  Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.

Authors:  Jade Cury-Martins; Adriana Pessoa Mendes Eris; Cristina Martinez Zugaib Abdalla; Giselle de Barros Silva; Veronica Paula Torel de Moura; Jose Antonio Sanches
Journal:  An Bras Dermatol       Date:  2020-02-15       Impact factor: 1.896

Review 5.  Melanoma and Vitiligo: In Good Company.

Authors:  Cristina Maria Failla; Maria Luigia Carbone; Cristina Fortes; Gianluca Pagnanelli; Stefania D'Atri
Journal:  Int J Mol Sci       Date:  2019-11-15       Impact factor: 5.923

6.  Dosimetric Predictors of Acute and Chronic Alopecia in Primary Brain Cancer Patients Treated With Volumetric Modulated Arc Therapy.

Authors:  Silvia Scoccianti; Gabriele Simontacchi; Daniela Greto; Marco Perna; Francesca Terziani; Cinzia Talamonti; Maria Ausilia Teriaca; Giorgio Caramia; Monica Lo Russo; Emanuela Olmetto; Camilla Delli Paoli; Roberta Grassi; Vincenzo Carfora; Calogero Saieva; Pierluigi Bonomo; Beatrice Detti; Monica Mangoni; Isacco Desideri; Giulio Francolini; Vanessa Di Cataldo; Livia Marrazzo; Stefania Pallotta; Lorenzo Livi
Journal:  Front Oncol       Date:  2020-04-08       Impact factor: 6.244

Review 7.  Scalp cooling to prevent chemotherapy-induced alopecia.

Authors:  Giselle de Barros Silva; Kathryn Ciccolini; Aline Donati; Corina van den Hurk
Journal:  An Bras Dermatol       Date:  2020-06-16       Impact factor: 1.896

Review 8.  Art of prevention: The importance of dermatologic care when using aromatase inhibitors.

Authors:  Sara Behbahani; Amaris Geisler; Avani Kolla; Margaret Rush Dreker; Genevieve Kaunitz; Miriam K Pomeranz
Journal:  Int J Womens Dermatol       Date:  2021-07-17

Review 9.  Dermatologic conditions in women receiving systemic cancer therapy.

Authors:  Michelle N Ferreira; Julie Y Ramseier; Jonathan S Leventhal
Journal:  Int J Womens Dermatol       Date:  2019-11-07

10.  Effects of high-intensity training on the quality of life of cancer patients and survivors: a systematic review with meta-analysis.

Authors:  Ana Myriam Lavín-Pérez; Daniel Collado-Mateo; Xián Mayo; Gary Liguori; Liam Humphreys; Robert James Copeland; Alfonso Jiménez
Journal:  Sci Rep       Date:  2021-07-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.